US 9816074
Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
granted A61KA61K35/28
Quick answer
US patent 9816074 (Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells) held by Sangamo Therapeutics, Inc. expires Mon Nov 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Sangamo Therapeutics, Inc.
- Grant date
- Tue Nov 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 9
- CPC classes
- A61K, A61K35/28